NCCN Guidelines® Insights - Ovarian Cancer, Version 2.2013

These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA 125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to NCCN Guidelines for ovarian cancer
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for ovarian cancer
Additional information
Supporters: 

Supported by educational grants from ARIAD Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.; CELGENE CORPORATION; Eisai Inc.; Endo Pharmaceuticals and HealthTronics; Genentech; Millennium: The Takeda Oncology Company; and Teva Pharmaceuticals

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
10/25/2013
Course expires: 
10/25/2014
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
10/25/2013
Course expires: 
10/25/2014

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing